Table 5.
Characteristics of the development cohort according to the risk group defined by the prognostic score at the time of transplantation, at the time of ABMR diagnosis, and at the time of the post-treatment evaluation
| Characteristic | Low-Risk Patients (n=202) | Intermediate-Risk Patients (n=36) | High-Risk Patients (n=40) | P |
|---|---|---|---|---|
| Baseline characteristics | ||||
| Recipient age (yr), mean±SD | 47.1±14.5 | 47.5±15.4 | 47.7±15.9 | 0.95 |
| Recipient sex (male), n (%) | 107 (53.0) | 17 (47.2) | 25 (62.5) | 0.39 |
| Retransplantation, n (%) | 67 (33.2) | 12 (33.3) | 10 (25.0) | 0.59 |
| Pre-emptive transplantation, n (%) | 26 (12.9) | 3 (8.3) | 5 (12.5) | 0.84 |
| Time since dialysis (yr), mean±SD | 5.7±5.5 | 5.0±5.3 | 4.4±4.1 | 0.69 |
| Donor age (yr), mean±SD | 48.9±17.2 | 55.7±10.1 | 55.1±17.3 | 0.04 |
| Donor sex (male), n (%) | 108 (53.5) | 22 (61.1) | 20 (50.0) | 0.60 |
| Donor type, n (%) | 0.03 | |||
| Living | 36 (17.8) | 4 (11.1) | 2 (5.0) | |
| Cerebrovascular death | 68 (33.7) | 17 (47.2) | 23 (57.5) | |
| Other cause of death | 98 (48.5) | 15 (41.7) | 15 (37.5) | |
| Terminal serum creatinine (µmol/L), mean±SD | 92.8±59.6 | 85.6±30.3 | 90.0±39.2 | 0.91 |
| Cold ischemia time (hours), mean±SD | 16.7±9.8 | 16.9±8.8 | 18.9±7.4 | 0.17 |
| HLA mismatch, mean±SD | ||||
| A | 1.1±0.6 | 1.1±0.6 | 1.2±0.7 | 0.63 |
| B | 1.4±0.6 | 1.2±0.8 | 1.4±0.7 | 0.17 |
| DR | 1.1±0.6 | 1.1±0.7 | 1.2±0.6 | 0.73 |
| Anti-HLA DSA at the time of transplantation, n (%) | 87 (43.1) | 9 (25.0) | 6 (15.0) | 0.001 |
| Characteristics at ABMR diagnosis | ||||
| GFR (ml/min per 1.73 m2), mean±SD | 38.0±19.5 | 29.5±9.9 | 22.4±10.5 | <0.001 |
| Proteinuria (g/g), mean±SD | 0.90±1.38 | 0.71±0.81 | 0.79±0.65 | 0.19 |
| Glomerulitis, mean±SD | 1.8±0.9 | 1.7±0.9 | 1.6±0.7 | 0.60 |
| Peritubular capillaritis, mean±SD | 2.0±0.8 | 1.8±0.8 | 1.9±0.6 | 0.29 |
| Interstitial inflammation, mean±SD | 0.6±1.0 | 1.0±1.1 | 0.8±1.0 | 0.03 |
| Tubulitis, mean±SD | 0.6±1.0 | 1.0±1.2 | 0.7±1.0 | 0.21 |
| Endarteritis, mean±SD | 0.4±0.9 | 0.3±0.8 | 0.4±0.9 | 0.53 |
| Chronic allograft glomerulopathy, mean±SD | 0.2±0.6 | 0.5±0.9 | 0.7±1.2 | <0.01 |
| Interstitial fibrosis/tubular atrophy, mean±SD | 0.7±0.9 | 1.8±1.0 | 1.7±1.0 | <0.001 |
| Arteriosclerosis, mean±SD | 1.1±1.0 | 1.6±1.0 | 1.8±1.0 | <0.001 |
| C4d deposition, mean±SD | 1.3±1.3 | 1.8±1.2 | 1.3±1.2 | 0.15 |
| Anti-HLA DSA MFI, mean±SEM | 4870.9±359.3 | 5856.3±914.0 | 6427.5±943.6 | 0.17 |
| Post-treatment characteristics | ||||
| GFR (ml/min per 1.73 m2), mean±SD | 47.7±17.5 | 27.6±7.1 | 17.3±5.0 | <0.001 |
| Proteinuria (g/g), mean±SD | 0.55±1.0 | 0.89±1.70 | 1.74±2.40 | <0.001 |
| Glomerulitis, mean±SD | 1.0±1.0 | 1.3±1.1 | 1.2±1.1 | 0.17 |
| Peritubular capillaritis, mean±SD | 1.1±1.0 | 1.3±1.0 | 1.7±1.0 | 0.002 |
| Interstitial inflammation, mean±SD | 0.2±0.5 | 0.4±0.8 | 0.3±0.7 | 0.54 |
| Tubulitis, mean±SD | 0.4±0.8 | 0.6±1.0 | 0.5±0.8 | 0.33 |
| Endarteritis, mean±SD | 0.1±0.4 | 0.03±0.2 | 0.08±0.3 | 0.53 |
| Chronic allograft glomerulopathy, mean±SD | 0.3±0.8 | 0.4±0.8 | 0.7±1.2 | 0.07 |
| Interstitial fibrosis/tubular atrophy, mean±SD | 1.1±1.0 | 1.9±1.1 | 2.0±1.1 | <0.001 |
| Arteriosclerosis, mean±SD | 1.3±1.0 | 1.7±0.9 | 1.7±0.9 | 0.03 |
| C4d deposition, mean±SD | 0.7±1.0 | 1.1±1.3 | 1.1±1.2 | 0.03 |
| Anti-HLA DSA MFI, mean±SEM | 2708.1±259.8 | 5089.6±975.5 | 6839.5±954.5 | <0.001 |